Nasdaq · Healthcare
UTAH MEDICAL PRODUCTS INC (UTMD)
As-reported financials and recent SEC filings for UTAH MEDICAL PRODUCTS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$38.5M
Net income
$11.3M
Net margin
29.3%
Diluted EPS
$3.48
ROE
9.5%
P/E (TTM)
—
Market cap
—
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $38.5M | $40.9M | $50.2M | $52.3M | $49.1M |
| Gross profit | $22.0M | $24.1M | $30.0M | $32.2M | $30.9M |
| Operating income | $11.4M | $13.6M | $16.8M | $19.8M | $18.9M |
| Net income | $11.3M | $13.9M | $16.6M | $16.5M | $14.8M |
| Diluted EPS | $3.48 | $3.96 | $4.57 | $4.52 | $4.04 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-01
View on EDGAR →42026-05-29
View on EDGAR →SD2026-05-27
View on EDGAR →SCHEDULE 13G/A2026-05-14
View on EDGAR →10-Q2026-05-12
View on EDGAR →8-K2026-05-04
View on EDGAR →8-K2026-04-23
View on EDGAR →DEF 14A2026-04-02
View on EDGAR →Largest Healthcare peers
Go deeper on UTMD
Search UTAH MEDICAL PRODUCTS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.